Abbott Laboratories - CEDEAR (ABT)
BCBA
39,740.00
-100.00 (-0.25%)
Closed
Oct 8, 2026
Day's Range
39,160.0039,800.00
52 wk Range
30,380.0052,525.00
Financial Statements - ABT - Abbott Laboratories - CEDEAR
Revenue
44.32B▼ 99.9%
Net Income
6.52B▼ 100.0%Net Margin 14.7%
EBITDA
12.02B▼ 99.9%
Free Cash Flow
7.39B▼ 99.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 44.32B | 60.17T | 40.10B | 43.65B | 43.07B | 34.60B |
| Cost of Goods | 19.31B | 26.83T | 17.97B | 19.14B | 18.53B | 15B |
| Gross Profit | 25B | 33.34T | 22.13B | 24.51B | 24.53B | 19.60B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 8.05B | 9.79T | 6.47B | 8.36B | 8.42B | 5.35B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 598M | 578.09B | 438M | 319M | 276M | 111M |
| Pre Tax Income | 8.46B | 10.05T | 6.66B | 8.30B | 8.21B | 4.96B |
| Income Tax | 1.94B | -9.16T | 941M | 1.37B | 1.14B | 497M |
| Net Income | 6.52B | 19.22T | 5.72B | 6.93B | 7.07B | 4.49B |
| EPS Basic | 7.513535 | 15.47845 | 6.600632 | 7.979077 | 8.016633 | 5.075568 |
| EPS Diluted | 7.44 | 15.28 | 6.52 | 7.82 | 7.88 | 5 |
| Basic Shares Outstanding | 868.29M | 1.24T | 819.35K | 822.81K | 835.26K | 838.64K |
| Diluted Shares Outstanding | 868.29M | 1.24T | 819.35K | 822.81K | 835.26K | 838.64K |
| Ebit | 8.95B | 10.86T | 7.30B | 8.86B | 8.74B | 5.51B |
| Ebitda | 12.02B | 15.43T | 10.58B | 12.13B | 12.28B | 8.83B |
| Net Income Continuous Operations | 6.52B | 19.22T | 5.72B | 6.93B | 7.07B | 4.49B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
